Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 7 | 2025 | 294 | 2.700 |
Why?
|
| RNA, Long Noncoding | 6 | 2025 | 248 | 2.080 |
Why?
|
| MicroRNAs | 8 | 2025 | 946 | 1.190 |
Why?
|
| Negative-Pressure Wound Therapy | 2 | 2025 | 19 | 1.150 |
Why?
|
| RNA, Untranslated | 3 | 2025 | 120 | 1.120 |
Why?
|
| Gene Regulatory Networks | 4 | 2018 | 400 | 1.050 |
Why?
|
| Fatty Acids | 3 | 2019 | 366 | 1.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2025 | 2136 | 1.000 |
Why?
|
| Dried Blood Spot Testing | 3 | 2023 | 27 | 0.980 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2025 | 151 | 0.860 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 3 | 2019 | 85 | 0.790 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 357 | 0.790 |
Why?
|
| Bevacizumab | 2 | 2025 | 80 | 0.770 |
Why?
|
| Wound Healing | 2 | 2025 | 483 | 0.750 |
Why?
|
| Transcriptome | 3 | 2025 | 1135 | 0.750 |
Why?
|
| Antibodies, Monoclonal | 3 | 2025 | 1049 | 0.750 |
Why?
|
| Metabolomics | 5 | 2024 | 471 | 0.680 |
Why?
|
| Cytokines | 1 | 2025 | 1381 | 0.610 |
Why?
|
| RNA, Neoplasm | 1 | 2018 | 146 | 0.560 |
Why?
|
| Chromatography, Liquid | 5 | 2025 | 245 | 0.560 |
Why?
|
| Neoplasms | 4 | 2025 | 3035 | 0.540 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 360 | 0.510 |
Why?
|
| Sequence Analysis, RNA | 3 | 2023 | 424 | 0.510 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2022 | 964 | 0.500 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 128 | 0.490 |
Why?
|
| Diabetes Mellitus | 1 | 2023 | 938 | 0.470 |
Why?
|
| RNA, Messenger | 3 | 2025 | 2885 | 0.460 |
Why?
|
| Immunoglobulin G | 1 | 2018 | 791 | 0.450 |
Why?
|
| Computational Biology | 4 | 2014 | 890 | 0.440 |
Why?
|
| Epistasis, Genetic | 1 | 2014 | 103 | 0.440 |
Why?
|
| RNA Interference | 2 | 2014 | 547 | 0.410 |
Why?
|
| Humans | 30 | 2025 | 133811 | 0.310 |
Why?
|
| Gene Expression Profiling | 5 | 2023 | 1917 | 0.280 |
Why?
|
| Reproducibility of Results | 5 | 2021 | 3047 | 0.270 |
Why?
|
| Radiation Tolerance | 2 | 2025 | 67 | 0.270 |
Why?
|
| Drug Monitoring | 2 | 2025 | 185 | 0.250 |
Why?
|
| Systems Biology | 1 | 2025 | 63 | 0.240 |
Why?
|
| Trastuzumab | 1 | 2025 | 154 | 0.230 |
Why?
|
| Ribonuclease III | 1 | 2025 | 103 | 0.230 |
Why?
|
| Cell Line, Tumor | 5 | 2025 | 3799 | 0.220 |
Why?
|
| Teicoplanin | 1 | 2024 | 5 | 0.220 |
Why?
|
| Digoxin | 1 | 2024 | 44 | 0.220 |
Why?
|
| Febrile Neutropenia | 1 | 2024 | 15 | 0.220 |
Why?
|
| Breast Neoplasms | 4 | 2020 | 2771 | 0.220 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2025 | 150 | 0.220 |
Why?
|
| Urinary Catheterization | 1 | 2024 | 87 | 0.220 |
Why?
|
| Plasma | 1 | 2023 | 105 | 0.200 |
Why?
|
| Catheter-Related Infections | 1 | 2024 | 139 | 0.200 |
Why?
|
| Digestion | 1 | 2021 | 45 | 0.180 |
Why?
|
| Hematocrit | 1 | 2021 | 116 | 0.180 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 294 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 555 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2024 | 297 | 0.170 |
Why?
|
| Carnitine | 1 | 2021 | 75 | 0.170 |
Why?
|
| Urinary Tract Infections | 1 | 2024 | 314 | 0.170 |
Why?
|
| Proteins | 4 | 2023 | 1099 | 0.160 |
Why?
|
| Solid Phase Microextraction | 1 | 2019 | 1 | 0.160 |
Why?
|
| Liquid-Liquid Extraction | 1 | 2019 | 12 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 3 | 2025 | 4823 | 0.160 |
Why?
|
| Cell Differentiation | 2 | 2025 | 2029 | 0.160 |
Why?
|
| Oncogenes | 2 | 2018 | 181 | 0.160 |
Why?
|
| RNA | 1 | 2023 | 606 | 0.150 |
Why?
|
| Sequence Analysis, Protein | 3 | 2008 | 49 | 0.150 |
Why?
|
| Vaccination | 1 | 2024 | 1019 | 0.150 |
Why?
|
| Genomics | 2 | 2025 | 1678 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 1 | 2025 | 739 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 231 | 0.150 |
Why?
|
| Subcellular Fractions | 2 | 2008 | 98 | 0.140 |
Why?
|
| Databases, Genetic | 2 | 2018 | 507 | 0.140 |
Why?
|
| Immobilized Proteins | 1 | 2017 | 5 | 0.140 |
Why?
|
| Calibration | 1 | 2018 | 100 | 0.140 |
Why?
|
| Bacterial Proteins | 2 | 2017 | 924 | 0.140 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 46 | 0.140 |
Why?
|
| Limit of Detection | 1 | 2017 | 77 | 0.140 |
Why?
|
| Magnets | 1 | 2017 | 23 | 0.140 |
Why?
|
| Mice | 6 | 2025 | 18936 | 0.130 |
Why?
|
| Disease Models, Animal | 2 | 2025 | 4760 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2018 | 224 | 0.130 |
Why?
|
| Microbiota | 1 | 2022 | 443 | 0.130 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 377 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 197 | 0.130 |
Why?
|
| MCF-7 Cells | 1 | 2017 | 233 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2019 | 252 | 0.130 |
Why?
|
| Cell Line | 2 | 2021 | 2861 | 0.130 |
Why?
|
| Voriconazole | 1 | 2014 | 34 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 769 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2014 | 183 | 0.110 |
Why?
|
| Genome, Human | 1 | 2021 | 1350 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 623 | 0.110 |
Why?
|
| Neuroblastoma | 1 | 2019 | 551 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2014 | 437 | 0.100 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 125 | 0.100 |
Why?
|
| Animals | 6 | 2025 | 36222 | 0.100 |
Why?
|
| Cell Proliferation | 1 | 2020 | 2559 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1036 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 2575 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2014 | 305 | 0.090 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2018 | 865 | 0.090 |
Why?
|
| Binding Sites | 1 | 2014 | 1379 | 0.090 |
Why?
|
| Protein Structure, Secondary | 3 | 2008 | 256 | 0.090 |
Why?
|
| Proteomics | 2 | 2006 | 605 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2014 | 478 | 0.090 |
Why?
|
| Algorithms | 3 | 2014 | 1736 | 0.090 |
Why?
|
| Cell Survival | 2 | 2025 | 886 | 0.090 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2025 | 249 | 0.080 |
Why?
|
| Lung Neoplasms | 1 | 2021 | 1783 | 0.080 |
Why?
|
| Female | 9 | 2024 | 71840 | 0.080 |
Why?
|
| Gram-Negative Bacteria | 2 | 2007 | 74 | 0.080 |
Why?
|
| Male | 6 | 2025 | 65939 | 0.080 |
Why?
|
| Dipeptides | 1 | 2008 | 64 | 0.070 |
Why?
|
| Glioblastoma | 1 | 2011 | 372 | 0.070 |
Why?
|
| Sequence Alignment | 1 | 2007 | 631 | 0.060 |
Why?
|
| Biotransformation | 1 | 2024 | 56 | 0.060 |
Why?
|
| Microbial Interactions | 1 | 2024 | 17 | 0.060 |
Why?
|
| Biomarkers | 1 | 2014 | 3422 | 0.060 |
Why?
|
| Inflammation | 2 | 2024 | 1570 | 0.050 |
Why?
|
| Pancreas | 1 | 2025 | 231 | 0.050 |
Why?
|
| Mutation | 1 | 2018 | 6350 | 0.050 |
Why?
|
| Methanol | 1 | 2023 | 14 | 0.050 |
Why?
|
| Indicators and Reagents | 1 | 2023 | 52 | 0.050 |
Why?
|
| Young Adult | 3 | 2024 | 9926 | 0.050 |
Why?
|
| Membrane Proteins | 2 | 2008 | 1618 | 0.050 |
Why?
|
| Aged | 4 | 2024 | 21714 | 0.050 |
Why?
|
| Relative Biological Effectiveness | 1 | 2021 | 8 | 0.050 |
Why?
|
| Acetylcarnitine | 1 | 2021 | 3 | 0.040 |
Why?
|
| Oxides | 1 | 2021 | 15 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 721 | 0.040 |
Why?
|
| Methylamines | 1 | 2021 | 20 | 0.040 |
Why?
|
| Machine Learning | 1 | 2024 | 344 | 0.040 |
Why?
|
| Middle Aged | 4 | 2024 | 29287 | 0.040 |
Why?
|
| Protons | 1 | 2021 | 98 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 404 | 0.040 |
Why?
|
| Choline | 1 | 2021 | 56 | 0.040 |
Why?
|
| Carbon | 1 | 2021 | 98 | 0.040 |
Why?
|
| 3T3-L1 Cells | 1 | 2020 | 58 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2020 | 85 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2024 | 1728 | 0.040 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2020 | 52 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 121 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 781 | 0.040 |
Why?
|
| Coculture Techniques | 1 | 2020 | 245 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 167 | 0.040 |
Why?
|
| Gene Drive Technology | 1 | 2019 | 6 | 0.040 |
Why?
|
| Lipids | 1 | 2023 | 565 | 0.040 |
Why?
|
| Adipocytes | 1 | 2020 | 179 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 218 | 0.040 |
Why?
|
| Inflammation Mediators | 1 | 2020 | 253 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 224 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2008 | 2785 | 0.040 |
Why?
|
| K562 Cells | 1 | 2018 | 100 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2018 | 98 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2020 | 441 | 0.040 |
Why?
|
| RNA Precursors | 1 | 2018 | 69 | 0.040 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 202 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2008 | 3966 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2019 | 152 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2020 | 686 | 0.030 |
Why?
|
| Protein Domains | 1 | 2018 | 260 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2018 | 177 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2018 | 439 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2020 | 509 | 0.030 |
Why?
|
| United States | 2 | 2024 | 11760 | 0.030 |
Why?
|
| Probability | 2 | 2008 | 332 | 0.030 |
Why?
|
| Adult | 3 | 2024 | 31823 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2018 | 787 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2022 | 1834 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2019 | 1593 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 697 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2024 | 3746 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2018 | 1147 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2018 | 897 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2018 | 829 | 0.030 |
Why?
|
| Base Sequence | 1 | 2018 | 3169 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6602 | 0.030 |
Why?
|
| Incidence | 1 | 2019 | 3416 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2018 | 1146 | 0.020 |
Why?
|
| Software | 2 | 2006 | 735 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2011 | 261 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2019 | 2730 | 0.020 |
Why?
|
| Obesity | 1 | 2020 | 2445 | 0.020 |
Why?
|
| Prognosis | 1 | 2018 | 5071 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2024 | 13114 | 0.020 |
Why?
|
| Solubility | 1 | 2008 | 140 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 1485 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2014 | 3644 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 3506 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2007 | 670 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2019 | 4922 | 0.020 |
Why?
|
| Bacteriorhodopsins | 1 | 2006 | 3 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 17577 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2007 | 608 | 0.020 |
Why?
|
| Protein Sorting Signals | 1 | 2006 | 40 | 0.020 |
Why?
|
| Solvents | 1 | 2006 | 46 | 0.020 |
Why?
|
| Protein Folding | 1 | 2006 | 222 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 873 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2006 | 483 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2006 | 397 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2006 | 507 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2014 | 7195 | 0.010 |
Why?
|
| Child | 1 | 2023 | 25882 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2006 | 710 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2008 | 2303 | 0.010 |
Why?
|
| Peptides | 1 | 2006 | 863 | 0.010 |
Why?
|
| Adolescent | 1 | 2014 | 20610 | 0.010 |
Why?
|